Why ImmunityBio, Inc. (IBRX) Surged Last Week

We recently published a list of These 10 Firms Are On Fire Today. In this article, we are going to take a look at where ImmunityBio, Inc. (NASDAQ:IBRX) stands against other stocks that surged yesterday.

Wall Street’s main indices were a mixed bag anew on Thursday, with the tech-heavy Nasdaq the sole loser, as investors continued to digest results of more corporate earnings and key economic data.

The Nasdaq was down by 0.18 percent. In contrast, the Dow Jones grew by 0.65 percent while the S&P 500 rose by 0.41 percent.

Beyond the major indices, 10 companies finished stronger on the back of impressive corporate earnings and planned mergers and acquisitions. In this article, we explore the specific reasons behind their surge.

To come up with the list, we considered only the stocks with a $2 billion market capitalization and $5 million in trading volume.

ImmunityBio, Inc. (NASDAQ:IBRX)

ImmunityBio rallied by 7.23 percent on Thursday to end at $2.67 apiece following a strong earnings performance and ratings upgrade from investment companies.

In its earnings release, ImmunityBio, Inc. (NASDAQ:IBRX) said it narrowed its net loss attributable to stockholders by 3.3 percent to $129.6 million from the $134.1 million registered in the same period last year, as revenues skyrocketed by 41,192 percent to $16.5 million from only $40,000 in the same period last year.

The higher revenues were driven by the strong performance of its Anktiva, an immunotherapy treatment for non-muscle invasive bladder cancer (NMIBC). According to the company, it continues to experience steady growth as urologists increase their use of the said treatment.

Following the results, two investment firms gave a “buy” recommendation on its stock.

It also earned an $8 price target from HC Wainwright and a $6 price target from BTIG.

Overall, IBRX ranks 6th on our list of stocks that surged last week. While we acknowledge the potential of IBRX as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than IBRX but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.